A delegation from the company met with Hon’ble Minister for Industries & Commerce, Mr D. Sridhar Babu, and CEO of Telangana Lifesciences, Mr Shakthi M. Nagappan, to formally convey the decision and share details of their proposed plans.

Headquartered in Switzerland and founded in 1897, Lonza operates across more than 30 sites worldwide and employs close to 20,000 professionals. In 2025, the company reported sales of CHF 6.5 billion and a Core EBITDA of CHF 2.1 billion.

The decision follows an extensive evaluation process from which Hyderabad was identified as a preferred destination based on its strong talent pool, quality infrastructure, and supportive industrial ecosystem.

Over the past several months, senior representatives of Lonza have engaged with Telangana Lifesciences, the Industries & Commerce Department, and other stakeholders, which further reinforced the company’s confidence in Hyderabad as the right location for this investment.

Mr D. Sridhar Babu, Hon’ble Minister for Industries and Commerce, Government of Telangana, said, “We are thrilled to welcome Lonza’s decision to establish its new centre in Hyderabad. The city continues to stand out as the bright spot for global life sciences investments, driven by its strong scientific ecosystem, digital depth, and world-class manufacturing capabilities. Lonza’s investment further strengthens Telangana’s position as a preferred destination for innovation-led growth in the global biopharmaceutical industry. I am delighted that the centre has the potential to create a substantial number of new jobs over the years. We remain committed to supporting such endeavours that promise job creation for our citizens.”

Mr Shakthi M. Nagappan, CEO, Telangana Lifesciences, said, “We are delighted that Lonza has chosen Hyderabad for this expansion. This decision marks another significant milestone in the continued expansion of Telangana’s life sciences ecosystem. We look forward to working closely with Lonza to ensure the successful execution of this project and to enable long-term value creation.”

The new GCC is expected to contribute to the generation of high-value employment and further integrate Hyderabad into the global biopharmaceutical value chain.

The post Lonza Selects Hyderabad as new GCC location, Reinforcing Telangana’s Global Life Sciences Leadership appeared first on newsmantra.in l Latest news on Politics, World, Bollywood, Sports, Delhi, Jammu & Kashmir, Trending news | News Mantra.

Over the past few years, Hyderabad has witnessed:

·       Rapid expansion of global pharma and biotech GCCs

·       Strengthened biologics and vaccine manufacturing capacity

·       New investments in bioprocess design, advanced therapies, and AI-enabled healthcare

BioAsia 2026 is expected to further accelerate this momentum by catalyzing strategic partnerships that extend beyond the two-day event.

This year, BioAsia marks a significant advancement driven by transformative shifts and continued growth in the life sciences sector, with a strong spotlight on the TechBio inflection point where biology converges with AI and automation.

The announcement of the Next-Gen Life Sciences Policy at the World Economic Forum in Davos earlier this year, along with key strategic investments, has positioned Hyderabad as a prominent player on the global life sciences stage while reinforcing Telangana’s ecosystem across pharmaceuticals, biotechnology, and CRDMO services.

BioAsia 2026 represents a decisive shift toward execution, scale, and global competitiveness, reflecting the rapid evolution of the life sciences ecosystem. The event convenes high-impact global voices through plenaries, forward-looking panel dialogues, immersive exhibition engagement, expanded B2B partnering, and deeper cross-border collaboration, all centred on the TechBio inflection point, digital transformation, advanced biologics, and next-generation manufacturing.

Strategic discussions will examine how innovation progresses from laboratory discovery to clinical and commercial execution, with particular emphasis on AI as an enabler of speed, efficiency, and smarter decision-making across the life sciences value chain. Global sessions will spotlight emerging therapeutic modalities, AI-driven drug discovery, automation-enabled biomanufacturing, digital health ecosystems, and resilient supply networks. Moving beyond announcements, BioAsia 2026 is designed to catalyze actionable partnerships, fostering operational collaborations, R&D acceleration, and technology integration that translate dialogue into measurable outcomes.

Telangana, under the leadership of Mr. Revanth Reddy, Hon’ble Chief Minister and Mr. D. Sridhar Babu, Hon’ble Minister for Industries, amplified the Next-Gen Life Sciences Policy during the 2026 World Economic Forum Annual Meeting in Davos, positioning the state among the world’s leading life sciences clusters and accelerating its global investment outreach. This alignment synchronizes Telangana’s ambitions with global priorities such as sustainability, digital health, precision medicine, and supply chain diversification.

The state has evolved from a generics-led manufacturing base into a diversified, innovation-driven bioeconomy characterized by strong R&D capabilities and TechBio integration. The momentum generated by Telangana’s Next-Gen Life Sciences Policy, combined with BioAsia’s global stature, continues to propel the state forward as a leading hub for life sciences and healthcare innovation.

The post BioAsia 2026 Positions Telangana as a Global TechBio Powerhouse appeared first on newsmantra.in l Latest news on Politics, World, Bollywood, Sports, Delhi, Jammu & Kashmir, Trending news | News Mantra.